Wat is de prijs voor Vaxxinity, Inc. (VAXX)

Het prijs van Vaxxinity, Inc. (VAXX) is $0.0001

Wat is de marktkapitalisatie voor Vaxxinity, Inc. (VAXX)

Marktkapitalisatie voorVaxxinity, Inc. (VAXX) is $12.68K

Vaxxinity, Inc. (VAXX) Prijs en Marktkapitalisatie

Vaxxinity, Inc., a biotechnology company founded in 2014 and headquartered in Dallas, Texas, is dedicated to advancing novel therapeutic candidates for human application in the United States. Its primary areas of focus are neurological disorders and infectious diseases, particularly those caused by coronaviruses. The company's pipeline features several key programs: UB-311 is a Phase 2 clinical trial candidate targeting toxic aggregated amyloid-beta proteins in the brain, aiming to treat Alzheimer's disease. UB-312, currently in Phase 1 clinical trials, is an investigational therapy designed to address Parkinson's disease and other synucleinopathies, including Lewy body dementia and multiple system atrophy, by targeting detrimental aggregated alpha-synuclein. An anti-tau product candidate is also under development for various neurodegenerative conditions, such as Alzheimer's disease. UB-313 is being developed to alleviate migraines by modulating calcitonin gene-related peptide. An anti-PCSK9 candidate aims to lower low-density lipoprotein cholesterol and reduce the risk of cardiac events by targeting proprotein convertase subtilisin/kexin type 9 serine protease. In the infectious disease segment, UB-612 is a Phase 3 clinical-stage candidate engineered to neutralize the SARS-CoV-2 virus.

Prijs voor VAXX	Aandeel B	Marktkapitalisatie van B	uitslagen
$42,462.21 $12.68K	NVDA	$5.383T	+42,462,213,656.11%
$34,890.29 $12.68K	AAPL	$4.423T	+34,890,291,773.62%
$32,815.66 $12.68K	GOOG	$4.160T	+32,815,660,091.53%
$28,895.10 $12.68K	MSFT	$3.663T	+28,895,100,365.37%
$22,805.09 $12.68K	AMZN	$2.891T	+22,805,085,839.42%

Prijs voor VAXX

Aandeel B

Marktkapitalisatie van B

uitslagen

$42,462.21 $12.68K